An Early-Exercise-Probability Perspective of American Put Options in the Low-Interest-Rate Era.
- Published in:
- Journal of Futures Markets, 2015, v. 35, n. 12, p. 1154, doi. 10.1002/fut.21700
- By:
- Publication type:
- Article
Works by Wan, Chao-Ling
Results: 18
1
2
Analysis of a jump-diffusion option pricing model with serially correlated jump sizes.
- Published in:
- Communications in Statistics: Theory & Methods, 2018, v. 47, n. 4, p. 953, doi. 10.1080/03610926.2017.1315731
- By:
- Publication type:
- Article
3
Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on International Consensus Classification.
- Published in:
- 2024
- By:
- Publication type:
- Letter
4
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00982-3
- By:
- Publication type:
- Article
5
Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00837-3
- By:
- Publication type:
- Article
6
Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL.
- Published in:
- 2023
- By:
- Publication type:
- Letter
7
A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.797941
- By:
- Publication type:
- Article
8
A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia.
- Published in:
- Frontiers in Oncology, 2021, v. 12, p. 1, doi. 10.3389/fonc.2021.726926
- By:
- Publication type:
- Article
9
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
- Published in:
- 2021
- By:
- Publication type:
- Letter
10
Chidamide combined with azacitidine as a novel double epigenetic preemptive treatment for a myelodysplastic syndrome patient showing molecular relapse after allogeneic hematopoietic stem cell transplantation.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 12, p. 6003, doi. 10.1007/s00277-024-06137-5
- By:
- Publication type:
- Article
11
Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 9, p. 2397, doi. 10.1007/s00277-023-05236-z
- By:
- Publication type:
- Article
12
Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 8, p. 2001, doi. 10.1007/s00277-023-05286-3
- By:
- Publication type:
- Article
13
Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 1, p. 155, doi. 10.1007/s00277-022-05040-1
- By:
- Publication type:
- Article
14
Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.841276
- By:
- Publication type:
- Article
15
Mutation spectrum of FLT3 and significance of non‐canonical FLT3 mutations in haematological malignancy.
- Published in:
- British Journal of Haematology, 2023, v. 202, n. 3, p. 539, doi. 10.1111/bjh.18877
- By:
- Publication type:
- Article
16
Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
17
Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome‐positive acute myeloid leukemia: A case report.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
18
Efficiency of anti‐VEGF therapy in central nervous system AML relapse: A case report and literature review.
- Published in:
- Clinical Case Reports, 2022, v. 10, n. 2, p. 1, doi. 10.1002/ccr3.5367
- By:
- Publication type:
- Article